Regulus Therapeutics, Inc. ( Regulus Therapeutics)

Primary tabs

Regulus Therapeutics's picture

Management

Contact Address

About Regulus Therapeutics, Inc.

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field.

Regulus Therapeutics press release, blog etc

Thu, 03/06/2025 - 20:34 Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
Tue, 02/04/2025 - 18:00 Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Wed, 07/10/2024 - 23:16 Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Tue, 06/04/2024 - 17:45 Regulus Therapeutics Announces Expected Addition to the Russell 3000 and Russell 2000 Indexes
Fri, 05/17/2024 - 00:46 Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Mon, 12/12/2022 - 13:25 Regulus Therapeutics Announces Resignation of Board Member
Mon, 11/28/2022 - 19:35 Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations
Wed, 11/02/2022 - 16:56 Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Thu, 10/27/2022 - 09:21 Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
Thu, 09/01/2022 - 19:03 Regulus Therapeutics to Participate in Upcoming Investor Conferences
Tue, 06/21/2022 - 04:52 Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mon, 06/13/2022 - 07:35 Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Thu, 06/02/2022 - 00:31 Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK
Tue, 05/17/2022 - 19:01 Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Wed, 05/11/2022 - 00:58 Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Wed, 03/23/2022 - 22:27 Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital
Thu, 02/24/2022 - 19:29 Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome
Thu, 02/10/2022 - 18:42 Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
more

InfoBox

HomePagewww.regulusrx.com
Twittertwitter.com/RegulusRx
LinkedInwww.linkedin.com/company/regulus-therapeutics
Wikipediaen.wikipedia.org/wiki/Regulus_Therapeutics